Back to top
more

IntelGenx Technologies (IGXT)

(Delayed Data from OTC)

$0.18 USD

0.18
16,400

+0.01 (5.88%)

Updated Apr 16, 2024 03:27 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IntelGenx (IGXT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

IntelGenx (IGXT) delivered earnings and revenue surprises of -50.00% and 102.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will IntelGenx (IGXT) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

IntelGenx (IGXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA

by Zacks Equity Research

IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.

IntelGenx (IGXT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

IntelGenx (IGXT) delivered earnings and revenue surprises of -50.00% and -78.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will IntelGenx (IGXT) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

IntelGenx (IGXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts IntelGenx's (IGXT) NDA resubmssion for its migraine candidate Rizaport 10 mg. The stock appreciates.

IntelGenx (IGXT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

IntelGenx (IGXT) delivered earnings and revenue surprises of -33.33% and 250.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: IntelGenx (IGXT) Q3 Earnings Expected to Decline

by Zacks Equity Research

IntelGenx (IGXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IntelGenx (IGXT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

IntelGenx (IGXT) delivered earnings and revenue surprises of 0.00% and 134.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?